Nasheed Mohammad Hossain, MD

Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Headshot of Nasheed Mohammad Hossain, MD
Penn Medicine Provider

About me

  • Ann B. Young Assistant Professor in Cancer Research

My education and training

  • Medical School: Case Western Reserve University School of Medicine
  • Residency: University of Chicago Medical Center
  • Fellowship: Fox Chase Cancer Center
  • Fellowship: Stanford University Medical Center

Spoken languages

English
English
বাংলা
Bengali

Reviews

Average Rating

141 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
May 2026
very caring informative and strong interpersonal skills
Anonymous
May 2026
dr nash is saving my life
Anonymous
February 2026
dr. nash is an excellent doctor with exceptional communication skills
Anonymous
February 2026
he's an exceptional physician and professional.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Hossain is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Schneider M, Paruzzo L, Stella F, Noll JH, Ho M, Babatunde V, Ho B, Devi P, Chong EA, Barta SK, Nasta SD, Svoboda J, Carter J, Cook MR, Hossain NM, Thomas CJ, Patel V, de Souza VB, Alkhatib MH, Li Z, Tan M, Michener P, Guruprasad P, Imparato A, Carturan A, Porazzi P, Fraietta JA, Schuster SJ, Maillard I, Ruella M, Landsburg DJ. Naïve CD4(+) T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy , Nat Commun: 2026


Wang T, Ferreira AC, Hossain NM, Fu D, Hill EG, Jimenez Jimenez AM, Benjamin C, Komanduri KV, Paczesny S. Day-30 IL1RL1, CXCL9 and REG3α are prognostic for survival after mismatched unrelated donor transplantation , Br J Haematol: 2026


Baron J, Chelius M, Cohen L, Perez CC, Riina M, Ramesh S, Tierney A, Elghawy O, Hossain NM, Rook A, Villasenor-Park J, Samimi S, Kim E, Hubbeling H, Plastaras JP, Barta SK, LaRiviere M. Standard Versus Hypofractionated Low-Dose Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma: A Single-Institution Retrospective Analysis , Pract Radiat Oncol: 2026


Mirza AS, Hosing C, Foss F, Kim S, Moskop A, Oloyede T, Abid MB, Afrough A, Ahmed S, Badar T, Barba P, Bhatt VR, Brown VI, Dahiya S, Deol A, Epperla N, Ganguly S, Grover NS, Hashmi H, Hashmi S, Hematti P, Hildebrandt GC, Hill JM Jr, Hossain NM, Ibrahim U, Johnson PC, Kharfan-Dabaja MA, Krem MM, Lekakis LJ, Maziarz RT, Murthy HS, Riedell PA, Salas MQ, Shouse G, Strouse C, Thakar MS, Turtle CJ, Woolfrey A, Wudhikarn K, Yared JA, Pasquini MC, Gowda L. Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas , Blood Neoplasia, 3: 2025,100187


Rangarajan HG, Satwani P, Herr MM, Chen M, Martens MJ, Wudhikarn K, John S, Fabrizio VA, Hsieh EM, Kelkar AH, Doherty E, Marks DI, Ringden O, Friend BD, Kelly MS, Farhadfar N, Prestidge T, Hossain NM, Liu H, Hashmi S, Modi D, Winestone LE, El Boghdadly Z, Murthy HS, Perales MA, Chemaly RF, Dandoy CE, Hill JA, Huppler AR, Riches M, Auletta JJ. Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis , Blood Adv, 9: 2025,5489-5500


Hossain NM, Ahn KW, Patel J, Lian Q, Abid B, Al Nughmush A, Bacher U, Bi X, Hashmi SK, Hilal T, Husnain M, Khimani F, Maziarz RT, Modi D, Ram R, Rizzieri D, Sica RA, Steinberg A, Vij R, Shadman M, Turtle C, Hamadani M, Herrera AF. Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS , Br J Haematol: 2025


Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ. Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen , Eur J Haematol, 114(4): 2025,626-635


Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission , Blood Cancer J, 14(1): 2024,108


Khera N, Ailawadhi S, Brazauskas R, Patel J, Jacobs B, Ustun C, Ballen K, Abid MB, Diaz Perez MA, Al-Homsi AS, Hashem H, Hong S, Munker R, Schears RM, Lazarus HM, Ciurea S, Badawy SM, Savani BN, Wirk B, LeMaistre CF, Bhatt NS, Beitinjaneh A, Aljurf M, Sharma A, Cerny J, Knight JM, Kelkar AH, Yared JA, Kindwall-Keller T, Winestone LE, Steinberg A, Arnold SD, Seo S, Preussler JM, Hossain NM, Fingrut WB, Agrawal V, Hashmi S, Lehmann LE, Wood WA, Rangarajan HG, Saber W, Hahn T. Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities , Blood Adv, 8(13): 2024,3497-3506


Wang TP, Ahn KW, Shadman M, Kaur M, Ahmed N, Bacher U, Cerny J, Chen A, Epperla N, Frigault M, Grover N, Haverkos B, Hill B, Hossain N, Iqbal M, Jain T, Krem MM, Maakaron J, Modi D, Alhaj Moustafa M, Riedell P, Savani B, Sica RA, Sureda A, Wudhikarn K, Herrera AF, Sauter C, Hamadani M, Jimenez Jimenez A. Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis , Leukemia, 38(7): 2024,1564-1569